<DOC>
	<DOCNO>NCT02278276</DOCNO>
	<brief_summary>The purpose study determine safety benefit SG1002 , include overcome deficit circulate hydrogen sulfide nitrite find heart failure patient , secondary endpoint focus improve clinical endpoint .</brief_summary>
	<brief_title>Assessing Safety Bioactivity SG1002 Heart Failure Patients</brief_title>
	<detailed_description>This 3 month , placebo control double blind study , determine whether 800 mg SG1002 give twice daily safe improve circulating level hydrogen sulfide and/or nitrite heart failure subject . In addition , secondary endpoint 6 minute walk distance , Minnesota heart failure questionnaire , biomarkers inflammation oxidative stress cardiac remodeling assess .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>symptomatic heart failure , New York Heart Association ( NYHA ) classification stage III ; ambulatory ; leave ventricular ejection fraction le 40 % within 6 month screen ; heart failure stable previous 3 month ( define change baseline therapy symptom heart failure previous 3 month ) ( change diuretic permit ) ; female , either postmenopausal surgically sterilise willing use acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) signing informed consent form though Final Visit/Early Termination Visit ; willing able provide write informed consent . pregnant breastfeeding ; follow within 3 month prior screen : myocardial infarction , unstable angina , cerebrovascular accident , percutaneous coronary intervention , open heart surgery , cardiac resynchronisation therapy ( CRT ) transient ischaemic attack ( TIA ) ; serious cerebrovascular disease opinion PI ; unable walk without assistance another person ; primary lung disease major contributor current symptom status ; currently participate another interventional clinical study , participate one within 30 day prior screen ; inability speak English ( due need administer standardise Englishlanguage questionnaire ) ; current symptomatic hypotension ( define systolic blood pressure ( SBP ) ≤ 90 mmHg diastolic blood pressure ( DBP ) ≤ 40 mmHg ) ; poorly control hypertension ( define SBP ≥ 160 mmHg DBP ≥ 100 mmHg ) despite therapy ; percutaneous coronary intervention open heart surgery within 3 month screen visit ; serious liver disease ; poorly control diabetes ( define HbA1c &gt; 10.0 % ) ; hypersensitivity sulfur related compound ; use sulfur contain product supplement , dimethyl sulfoxide ( DMSO ) methylsulfonylmethane ( MSM ) ; renal insufficiency define eGFR &lt; 30 mL/minute/1.73 m2 ( Modification Diet Renal Disease Study MDRD ) ; life expectancy le 6 month ; active malignancy require active antineoplastic therapy , opinion Investigator , interfere study treatment participation . ( Stable basal cell skin cancer cancer treat solely hormonal therapy allow ) ; evidence drug alcohol abuse within past 3 year ; chronic illness may , opinion Investigator , increase risk associated trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>